Skip to main content

Table 3 P50 suppression amplitudes of S1, S2, and S1/S2 and latencies at different time points

From: Effects of bumetanide on neurodevelopmental impairments in patients with tuberous sclerosis complex: an open-label pilot study

 

TD (n = 31)

TSC (n = 7)

Time point

D0

D0

D91

D119

Trial

Mean amplitude (SD)

Mean amplitude (SD)

S1 amplitude

1.65 (1.01)

1.42 (.68)

1.98 (1.26)

1.67 (1.38)

S1 latency

61.35 (10.39)

62.67 (11.40)

63.33 (9.06)

62.67 (9.95)

S2 amplitude

1.00 (1.04)

.88 (.70)

1.02 (.89)

.74 (.52)

S2 latency

59.27 (15.45)

65 (9.97)

67.75 (14.44)

66.22 (14.12)

S1/S2 ratio

.58 (.55)

.73 (.50)

.81 (.85)

.65 (.52)

  1. Abbreviations: TD typically developing controls, TSC tuberous sclerosis complex